0001569769-23-000007.txt : 20231016
0001569769-23-000007.hdr.sgml : 20231016
20231016160632
ACCESSION NUMBER: 0001569769-23-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231013
FILED AS OF DATE: 20231016
DATE AS OF CHANGE: 20231016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Soni Manmeet Singh
CENTRAL INDEX KEY: 0001569769
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 231327403
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS, INC.
STREET 2: 995 EAST ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wk-form4_1697486782.xml
FORM 4
X0508
4
2023-10-13
0
0001599298
Summit Therapeutics Inc.
SMMT
0001569769
Soni Manmeet Singh
C/O SUMMIT THERAPEUTICS INC.
2882 SAND HILL ROAD, SUITE 106
MENLO PARK
CA
94025
1
1
0
0
Chief Operating Officer
0
Common Stock
2023-10-13
4
P
0
2976190
1.68
A
2976190
D
Stock Option (right to buy)
1.68
2023-10-13
4
A
0
14000000
A
2033-10-13
Common Stock
14000000
14000000
D
The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68.
The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 14,000,000 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets.
Not applicable.
/s/ Manmeet Soni
2023-10-16